血液神经丝轻链水平可区分多发性硬化治疗效应
研究纳入1261例开始新型疾病修饰治疗的复发缓解型多发性硬化瑞典患者,分析血浆神经丝轻链浓度与临床变量及治疗药物的关联。结果显示不同药物间pNfL下降幅度和治疗中水平存在差异,阿仑单抗下降最大且治疗中水平最低,特立氟胺下降最小且治疗中水平最高但基线较低。
要点
- 基线pNfL与复发率、EDSS评分等正相关,与SDMT表现负相关。
- 不同DMT间pNfL下降幅度和治疗中水平存在显著差异。
- 阿仑单抗降低pNfL最显著,特立氟胺降低幅度最小。
核心结论
- 在RRMS中,DMT选择与pNfL下降程度显著相关,支持pNfL作为药物反应标志物。
研究设计与样本
- 对1261例开始新型DMT的瑞典RRMS患者进行线性回归分析,校正基线因素采用逆倾向评分加权。
主要发现
- 基线pNfL与复发率、EDSS评分、ARMSS评分和MSIS-29正相关,与SDMT表现和既往DMT数量负相关。
- 从基线到治疗中pNfL的下降幅度及治疗中pNfL水平在不同DMT间存在差异。
- 阿仑单抗组pNfL下降最大且治疗中水平最低,特立氟胺组下降最小且治疗中水平最高但基线较低。
- 治疗中pNfL和pNfL下降幅度均高度依赖基线浓度。
临床怎么用
- pNfL可作为评估RRMS患者对DMT反应的潜在生物标志物,辅助治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine factors (including the role of specific disease modulatory treatments [DMTs]) associated with (1) baseline, (2) on-treatment, and (3) change (from treatment start to on-treatment assessment) in plasma neurofilament light chain (pNfL) concentrations in relapsing-remitting multiple sclerosis (RRMS). METHODS: Data including blood samples analyses and long-term clinical follow-up information for 1,261 Swedish patients with RRMS starting novel DMTs were analyzed using linear regressions to model pNfL and changes in pNfL concentrations as a function of clinical variables and DMTs (alemtuzumab, dimethyl fumarate, fingolimod, natalizumab, rituximab, and teriflunomide). RESULTS: The baseline pNfL concentration was positively associated with relapse rate, Expanded Disability Status Scale score, Age-Related MS Severity Score, and MS Impact Score (MSIS-29), and negatively associated with Symbol Digit Modalities Test performance and the number of previously used DMTs. All analyses, which used inverse propensity score weighting to correct for differences in baseline factors at DMT start, highlighted that both the reduction in pNfL concentration from baseline to on-treatment measurement and the on-treatment pNfL level differed across DMTs. Patients starting alemtuzumab displayed the highest reduction in pNfL concentration and lowest on-treatment pNfL concentrations, while those starting teriflunomide had the smallest decrease and highest on-treatment levels, but also starting from lower values. Both on-treatment pNfL and decrease in pNfL concentrations were highly dependent on baseline concentrations. CONCLUSION: Choice of DMT in RRMS is significantly associated with degree of reduction in pNfL, which supports a role for pNfL as a drug response marker.
引用
- Delcoigne B, Manouchehrinia A, Barro C, et al. Blood neurofilament light levels segregate treatment effects in multiple sclerosis. Neurology. 2020. PMID: 32047070. doi:10.1212/WNL.0000000000009097
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。